Neptune Technologies & Bioressources Inc. and subsidiary Acasti Pharma Inc. to Host Management Discussion Broadcast at 4:30 p.m. on Nov. 4th

Laval, Québec, CANADA – November 3, 2010 – Neptune Technologies & Bioressources Inc. (“Neptune”) (NASDAQ.NEPT - TSX.V.NTB) and its subsidiary, Acasti Pharma Inc. (“Acasti”), will host a management discussion on developments at Acasti during a November 4th Webex broadcast at 4:30 p.m. Eastern Daylight Time (“EDT”).

Due to technical difficulties, the Webex broadcast initially scheduled Wednesday, November 3rd at 8:30 a.m. EDT had to be cancelled, Neptune and Acasti management apologizes for the inconvenient. 

The Webex broadcast is rescheduled at 4:30 p.m. EDT on Thursday November 4th.

Management hosts will be Acasti President, Dr. Tina Sampalis and Chief Operating Officer, Pierre Lemieux as well as Neptune Vice-President, Administration & Finance, André Godin.

The discussion will centre on:
•    Milestones at Acasti since the beginning of operations in August 2008
•    Recent launch of Acasti’s new medical food called Onemia ™
•    Other related topics.

Viewers can listen in to the Webex broadcast through their phones while watching the power point presentation online.

-------------------------------------------------------
To watch the power point presentation on your computer:
-------------------------------------------------------
1. Go to https://intercallcanada.webex.com/intercallcanada/j.php?ED=147808332&UID=0&RT=NCMxMQ%3D%3D
2. Enter your name and email address.
3. Click "Join Now".
-------------------------------------------------------

TO SUBMIT EMAIL QUESTIONS BEFORE OR DURING THE BROADCAST SEND AN EMAIL TO: 

This e-mail address is being protected from spambots, you need JavaScript enabled to view it
Please refer to the management discussion broadcast.

-------------------------------------------------------
To listen to the company executives while they go through the power point:
-------------------------------------------------------

Call-in toll-free number: 1-866-468-0803  (US/Canada)
Call-in number: 1-647-4277545  (US/Canada)
Conference Code: 191 534 7247

-------------------------------------------------------
For assistance
-------------------------------------------------------
1. Go to https://intercallcanada.webex.com/intercallcanada/mc
2. On the left navigation bar, click "Support".

About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune’s products are marketed and distributed in over 20 countries worldwide.

About Acasti Pharma Inc.

Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma’s proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular conditions within the over-the-counter, medical food and prescription drug markets.

About NeuroBioPharm

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."